Daclatone 30 Tablet contains Daclatasvir 30 mg, a direct-acting antiviral (DAA) agent that targets the NS5A protein of the Hepatitis C virus (HCV). By inhibiting NS5A, Daclatasvir prevents viral RNA replication and viral assembly, helping achieve sustained virologic response (SVR) and reducing the risk of chronic liver damage. This mechanism makes it a cornerstone in modern HCV therapy.
Clinically, Daclatone 30 Tablet is used as part of combination therapy regimens with other DAAs, tailored according to HCV genotype, liver function status, and prior treatment history. It is suitable for both treatment-naïve and treatment-experienced patients, providing consistent antiviral efficacy while minimizing the risk of resistance.
The tablet is formulated to ensure precise dosing, optimal bioavailability, and reliable therapeutic outcomes. Regular administration under medical supervision helps maintain stable plasma levels of Daclatasvir, improving treatment adherence and patient response. Its high-quality formulation makes it suitable for hospitals, specialty hepatology clinics, and infectious disease centers that require consistent antiviral supply.
Daclatone 30 Tablet also contributes to overall liver health by preventing HCV-induced hepatic inflammation, fibrosis progression, and potential complications such as cirrhosis or hepatocellular carcinoma. It is an ideal solution for healthcare providers seeking effective, evidence-based antiviral therapy with proven clinical performance and safety.